董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Juliet Tammenoms Bakker | 女 | Independent Director | 64 | 23.50万美元 | 4.97 | 2026-01-31 |
| J. Andy Corley | 男 | Chairman of the Board | 70 | 28.25万美元 | 64.91 | 2026-01-31 |
| Robert Warner | 男 | Independent Director | 59 | 23.75万美元 | 4.10 | 2026-01-31 |
| Ron Kurtz | 男 | Co-President, Chief Executive Officer and Director | 63 | 465.07万美元 | 159.64 | 2026-01-31 |
| Shweta Singh Maniar | -- | Independent Director | -- | 22.50万美元 | 1.81 | 2026-01-31 |
| Tamara R. Fountain | -- | Independent Director | -- | 23.00万美元 | 3.55 | 2026-01-31 |
| William J. Link | 男 | Independent Director | 80 | 22.00万美元 | 5.91 | 2026-01-31 |
| Robert J. Palmisano | 男 | Independent Director | 81 | 23.50万美元 | 4.10 | 2026-01-31 |
| Julie B. Andrews | 女 | Independent Director | 55 | 24.00万美元 | 4.10 | 2026-01-31 |
| Raymond W. Cohen | 男 | Director | 67 | 30.56万美元 | 未持股 | 2026-01-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ron Kurtz | 男 | Co-President, Chief Executive Officer and Director | 63 | 465.07万美元 | 159.64 | 2026-01-31 |
| Eric Weinberg | 男 | Chief Business Development Officer | 65 | 285.51万美元 | 99.55 | 2026-01-31 |
| Ilya Goldshleger | -- | Co-President and Chief Operating Officer | 51 | 285.29万美元 | 53.88 | 2026-01-31 |
| Scott Gaines | -- | Chief Customer Officer | -- | 137.63万美元 | 7.25 | 2026-01-31 |
| Mark Wilterding | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2026-01-31 |
董事简历
中英对照 | 中文 | 英文- Juliet Tammenoms Bakker
-
Juliet Tammenoms Bakker自2018年3月起担任董事会成员，自2018年10月起担任薪酬委员会成员以及提名和公司治理委员会主席。自2007年1月以来，Tammenoms Bakker女士一直担任梦百合风险投资公司Longitude Capital Management Co.，LLC的董事总经理。Tammenoms Bakker女士拥有学士学位。他拥有康奈尔大学农业和生命科学学院的硕士学位和哈佛大学JohnF.Kennedy政府学院的硕士学位。
Juliet Tammenoms Bakker has served as a member of Ceribell, Inc.'s Board since April 2021. Ms. Tammenoms Bakker co founded Longitude Capital, a healthcare venture capital firm, where she has served as a Managing Director since 2006. Previously, Ms. Tammenoms Bakker served as a Managing Director of Pequot Ventures, a venture capital firm, where she founded the life sciences investment practice. Prior to Pequot Ventures, Ms. Tammenoms Bakker was an equity research analyst with Banque Paribas. Ms. Tammenoms Bakker currently serves on the board of directors of RxSight, Inc. and on the boards of directors of multiple privately held healthcare companies. Ms. Tammenoms Bakker previously served on the boards of directors of various other publicly traded companies, including Eargo, Inc., Axonics Modulation Technologies, Inc., and Venus Concept Inc. Ms. Tammenoms Bakker received an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University. - Juliet Tammenoms Bakker自2018年3月起担任董事会成员，自2018年10月起担任薪酬委员会成员以及提名和公司治理委员会主席。自2007年1月以来，Tammenoms Bakker女士一直担任梦百合风险投资公司Longitude Capital Management Co.，LLC的董事总经理。Tammenoms Bakker女士拥有学士学位。他拥有康奈尔大学农业和生命科学学院的硕士学位和哈佛大学JohnF.Kennedy政府学院的硕士学位。
- Juliet Tammenoms Bakker has served as a member of Ceribell, Inc.'s Board since April 2021. Ms. Tammenoms Bakker co founded Longitude Capital, a healthcare venture capital firm, where she has served as a Managing Director since 2006. Previously, Ms. Tammenoms Bakker served as a Managing Director of Pequot Ventures, a venture capital firm, where she founded the life sciences investment practice. Prior to Pequot Ventures, Ms. Tammenoms Bakker was an equity research analyst with Banque Paribas. Ms. Tammenoms Bakker currently serves on the board of directors of RxSight, Inc. and on the boards of directors of multiple privately held healthcare companies. Ms. Tammenoms Bakker previously served on the boards of directors of various other publicly traded companies, including Eargo, Inc., Axonics Modulation Technologies, Inc., and Venus Concept Inc. Ms. Tammenoms Bakker received an M.P.A. from the Harvard Kennedy School and a B.Sc. from the College of Agriculture and Life Sciences at Cornell University.
- J. Andy Corley
-
J.Andy Corley自2015年1月起担任董事会成员。Corley先生自2012年以来还担任NeuroLens，Inc.的董事会成员，在那里他目前担任董事会主席，并自2016年以来担任Flying L Partners的合伙人。Corley先生于1998年联合创立Eyeonics，Inc.，并担任其首席执行官和董事会主席，直到2008年2月该公司被出售给Bausch&Lomb，Inc.。2008年至2011年，Corley先生在Bausch&Lomb收购Eyeonics，Inc.后担任外科部门总裁。1987年，Corley先生还联合创立了Chiron Vision Corp.，这是一家专注于LASIK开发的公司，并担任屈光手术部门的总经理直到1997年12月。Corley先生获得Georgia Southern University工商管理学士学位。
J. Andy Corley has served as a member of board of directors since January 2015. Mr. Corley has also served as a board member of Neurolenses, Inc. since 2012 where he currently serves as Chairman of the Board, and has been a partner at Flying L Partners since 2016. Mr. Corley co-founded eyeonics, Inc. in 1998 and served as its Chief Executive Officer and Chairman of the Board until the company was sold to Bausch & Lomb, Inc. in February 2008. Mr. Corley then served as President of the Surgical Division at Bausch & Lomb following its acquisition of eyeonics, Inc from 2008 to 2011. Mr. Corley also co-founded Chiron Vision Corp., a company focused on the development of LASIK, in 1987 and served as General Manager of the Refractive Surgery Division until December 1997. Mr. Corley received a Bachelor of Business Administration degree from Georgia Southern University. - J.Andy Corley自2015年1月起担任董事会成员。Corley先生自2012年以来还担任NeuroLens，Inc.的董事会成员，在那里他目前担任董事会主席，并自2016年以来担任Flying L Partners的合伙人。Corley先生于1998年联合创立Eyeonics，Inc.，并担任其首席执行官和董事会主席，直到2008年2月该公司被出售给Bausch&Lomb，Inc.。2008年至2011年，Corley先生在Bausch&Lomb收购Eyeonics，Inc.后担任外科部门总裁。1987年，Corley先生还联合创立了Chiron Vision Corp.，这是一家专注于LASIK开发的公司，并担任屈光手术部门的总经理直到1997年12月。Corley先生获得Georgia Southern University工商管理学士学位。
- J. Andy Corley has served as a member of board of directors since January 2015. Mr. Corley has also served as a board member of Neurolenses, Inc. since 2012 where he currently serves as Chairman of the Board, and has been a partner at Flying L Partners since 2016. Mr. Corley co-founded eyeonics, Inc. in 1998 and served as its Chief Executive Officer and Chairman of the Board until the company was sold to Bausch & Lomb, Inc. in February 2008. Mr. Corley then served as President of the Surgical Division at Bausch & Lomb following its acquisition of eyeonics, Inc from 2008 to 2011. Mr. Corley also co-founded Chiron Vision Corp., a company focused on the development of LASIK, in 1987 and served as General Manager of the Refractive Surgery Division until December 1997. Mr. Corley received a Bachelor of Business Administration degree from Georgia Southern University.
- Robert Warner
-
Robert Warner已被提名加入我们的董事会，与本次发行结束同时生效，届时他还将担任薪酬委员会和公司治理与提名委员会的成员。Warner先生于2015年8月至2018年2月担任爱尔康视觉护理专营权爱尔康的总裁兼总经理。在此之前，Warner先生从2012年1月到2015年7月担任爱尔康美国和加拿大总裁，从2010年11月到2012年1月担任爱尔康加拿大和拉丁美洲总裁。从2005年1月到2010年10月，Warner先生在爱尔康公司担任越来越多的责任职位。沃纳先生是爱尔康公司执行领导团队的成员超过10年，并领导爱尔康公司从雀巢公司向诺华公司的多数股权过渡。Warner先生目前在两家私人医疗设备公司I Lumen Scientific和Eyeyon Medical的董事会任职（担任后者的董事长），也是Grace，The Grapevine Relief and Community Exchange的董事会成员。Warner先生拥有佩斯大学化学学士学位和罗格斯大学工商管理硕士学位。
Robert Warner has been nominated to join board of directors, effective concurrent with the closing of this offering, at which time he will also serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. Mr. Warner served as President and General Manager of Alcon Vision Care Franchise Alcon from August 2015 until February 2018. Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010 Mr. Warner served in increasing positions of responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i Lumen Scientific and EyeYon Medical (serving as Chairman for the latter), and is also a board member of GRACE, the Grapevine Relief and Community Exchange. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University. - Robert Warner已被提名加入我们的董事会，与本次发行结束同时生效，届时他还将担任薪酬委员会和公司治理与提名委员会的成员。Warner先生于2015年8月至2018年2月担任爱尔康视觉护理专营权爱尔康的总裁兼总经理。在此之前，Warner先生从2012年1月到2015年7月担任爱尔康美国和加拿大总裁，从2010年11月到2012年1月担任爱尔康加拿大和拉丁美洲总裁。从2005年1月到2010年10月，Warner先生在爱尔康公司担任越来越多的责任职位。沃纳先生是爱尔康公司执行领导团队的成员超过10年，并领导爱尔康公司从雀巢公司向诺华公司的多数股权过渡。Warner先生目前在两家私人医疗设备公司I Lumen Scientific和Eyeyon Medical的董事会任职（担任后者的董事长），也是Grace，The Grapevine Relief and Community Exchange的董事会成员。Warner先生拥有佩斯大学化学学士学位和罗格斯大学工商管理硕士学位。
- Robert Warner has been nominated to join board of directors, effective concurrent with the closing of this offering, at which time he will also serve as a member of the Compensation Committee and the Corporate Governance and Nominating Committee. Mr. Warner served as President and General Manager of Alcon Vision Care Franchise Alcon from August 2015 until February 2018. Prior to that, Mr. Warner served as President, U.S. and Canada, for Alcon from January 2012 to July 2015 and as President, Canada and Latin America, for Alcon from November 2010 to January 2012. From January 2005 to October 2010 Mr. Warner served in increasing positions of responsibility for Alcon. Mr. Warner was a member of the Alcon Executive Leadership Team for over 10 years and led the Alcon transition from Nestle to Novartis majority ownership. Mr. Warner currently serves on the board of directors of two private medical device companies, i Lumen Scientific and EyeYon Medical (serving as Chairman for the latter), and is also a board member of GRACE, the Grapevine Relief and Community Exchange. Mr. Warner holds a B.S. in Chemistry from Pace University and an MBA from Rutgers University.
- Ron Kurtz
-
Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego. - Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
- Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.
- Shweta Singh Maniar
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Tamara R. Fountain
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- William J. Link
-
William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
William J. Link has served as a member and chairperson of Board of Directors since November 2017. Dr. Link is the co founder of two healthcare investment firms: in 2016 Dr. Link co founded and is Managing Partner of Flying L Partners, and Dr. Link is a co founder and a Managing Director of Versant Ventures Management LLC, or Versant Ventures, which was founded in 1999. Dr. Link has also been a general partner at Brentwood Venture Capital, a venture capital firm and private equity company, since March 1998. Previously, Dr. Link served as founder, chairman, and chief executive officer of Chiron Vision Corporation, an ophthalmic medical device company which was sold to Bausch & Lomb, Inc. in 1997. Before his time with Chiron Vision Corporation, Dr. Link founded and served as president of American Medical Optics, or AMO, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of directors of AMO's successor company, Advanced Medical Optics, which was acquired by Abbott in 2009. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link also serves on the board of directors of several private companies and two public companies, RxSight, Inc. (Nasdaq: RXST) since 2016 and Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) since 2017. Dr. Link previously served on the board of directors of Second Sight Medical Products (Nasdaq: EYES) from 2003 until May 2020, Edwards Lifesciences Corp. (NYSE: EW) from May 2009 until May 2021, Glaukos Corporation (NYSE: GKOS) from June 2001 to December 2021, and Oyster Point Pharma, Inc. (Nasdaq: OYST) from July 2015 until March 2022. Dr. Link received a B.S., an M.S. and a Ph.D. in mechanical engineering from Purdue University. - William J. Link，自2016年11月起担任董事会成员。Link博士于2017年成立了Flying L Management，LLC，是管理合伙人。自1999年以来，Link博士一直担任Versant Ventures Management LLC的董事总经理和联合创始人。2009年5月起担任爱德华兹生命科学 Corp.董事会成员，2015年7月起担任Oyster Point Pharma Pharma，Inc.董事会成员，2001年6月起担任Lensar，Inc.董事会成员，2017年11月起担任TERM3，Tarsus Pharmaceuticals，Inc.董事会成员。在1999年11月共同创立Versant Ventures之前，Link博士在1998年至2020年期间是Brentwood Venture Capital的普通合伙人。1986年3月至1997年12月，Link博士是Chiron Vision Corp.的创始人、董事长和首席执行官。他还创立并担任1978年至1985年被Allergan，Inc.收购的American Medical Optics，Inc.的总裁。Link博士于2002年9月至2009年2月担任Advanced Medical Optics，Inc.董事、于2003年7月至2014年2月担任Inogen公司董事、于2003年8月至2020年5月担任Second Sight医疗产品公司董事。Link博士还曾在1973年至1976年期间担任印第安纳大学医学院外科系的助理教授。Link博士获得普渡大学机械工程学学士、硕士和博士学位。
- William J. Link has served as a member and chairperson of Board of Directors since November 2017. Dr. Link is the co founder of two healthcare investment firms: in 2016 Dr. Link co founded and is Managing Partner of Flying L Partners, and Dr. Link is a co founder and a Managing Director of Versant Ventures Management LLC, or Versant Ventures, which was founded in 1999. Dr. Link has also been a general partner at Brentwood Venture Capital, a venture capital firm and private equity company, since March 1998. Previously, Dr. Link served as founder, chairman, and chief executive officer of Chiron Vision Corporation, an ophthalmic medical device company which was sold to Bausch & Lomb, Inc. in 1997. Before his time with Chiron Vision Corporation, Dr. Link founded and served as president of American Medical Optics, or AMO, a division of American Hospital Supply Corporation, which was sold to Allergan in 1986. Later, he served on the board of directors of AMO's successor company, Advanced Medical Optics, which was acquired by Abbott in 2009. Before entering the healthcare industry, Dr. Link was an assistant professor in the Department of Surgery at the Indiana University School of Medicine. Dr. Link also serves on the board of directors of several private companies and two public companies, RxSight, Inc. (Nasdaq: RXST) since 2016 and Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) since 2017. Dr. Link previously served on the board of directors of Second Sight Medical Products (Nasdaq: EYES) from 2003 until May 2020, Edwards Lifesciences Corp. (NYSE: EW) from May 2009 until May 2021, Glaukos Corporation (NYSE: GKOS) from June 2001 to December 2021, and Oyster Point Pharma, Inc. (Nasdaq: OYST) from July 2015 until March 2022. Dr. Link received a B.S., an M.S. and a Ph.D. in mechanical engineering from Purdue University.
- Robert J. Palmisano
-
Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College. - Robert J. Palmisano，担任总裁兼首席执行官，并于2011年9月起担任Wright Medical Group, Inc.纳斯达克：WMGI的董事会执行董事和董事会成员，直至2020年11月其被史赛克公司（NYSE：SYK）收购。Palmisano先生于2008年4月至2010年7月被Covidien plc收购时担任ev3 Inc.的总裁兼首席执行官。Palmisano先生于2003年4月至2007年4月被Advanced Medical Optics，Inc.收购时担任IntraLase Corp.的总裁兼首席执行官。在加入IntraLase之前，Palmisano先生于2001年4月至2003年4月担任MacroChem Corporation的总裁兼首席执行官。Palmisano先生于2020年12月至今担任Priveterra Acquisition Corp.（纳斯达克：PMGMU）的董事会主席。Palmisano先生此前曾担任Avedro, Inc.董事会主席，并在ev3 Inc.、Osteotech，Inc.和Abbott Medical Optics，Inc.（均为上市公司）以及博士伦（Bausch & Lomb）（一家私营公司）的董事会任职。Palmisano先生拥有普罗维登斯学院政治学学士学位。
- Robert J. Palmisano served as President and Chief Executive Officer, and as the Executive Director of the Board of Directors and Board Member of Wright Medical Group, Inc. Nasdaq: WMGI from September 2011 until its acquisition by Stryker Corporation (NYSE: SYK) in November 2020. Mr. Palmisano served as President and Chief Executive Officer of ev3 Inc. from April 2008 to July 2010 when it was acquired by Covidien plc. Mr. Palmisano was President and Chief Executive Officer of IntraLase Corp. from April 2003 to April 2007 when it was acquired by Advanced Medical Optics, Inc. Before joining IntraLase, Mr. Palmisano was President and Chief Executive Officer of MacroChem Corporation from April 2001 to April 2003. Mr. Palmisano has served as Chairman of the Board of Priveterra Acquisition Corp. (Nasdaq: PMGMU) from December 2020 to present. Mr. Palmisano previously served as the Chairman of the Board of Avedro, Inc., and on the board of directors of ev3 Inc., Osteotech, Inc. and Abbott Medical Optics, Inc., all publicly held companies, and Bausch & Lomb, a privately held company. Mr. Palmisano holds a B.A. in Political Science from Providence College.
- Julie B. Andrews
-
Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW. - Julie B. Andrews，于2019年8月至2020年12月期间，Andrews女士曾在Wright Medical Group N.V。纳斯达克：WMGI担任全球金融高级副总裁一职，负责财务、会计、税务和财务职能。在Wright医疗任职期间，Andrews女士在几起成功的并购交易中发挥了关键的领导作用。其中包括牵头将髋关节和膝关节业务以约3亿美元出售给Microport的交易剥离和剥离，为Wright医疗以33亿美元的股权价值收购Tornier，N.V。提供领导监督，以及牵头将Wright医疗出售给史赛克 Corp.的尽职调查和整合规划。Andrews女士于2012年5月至2019年9月担任Wright Medical Group N.V。（F.K.a。 赖特医疗集团 Inc.）的副总裁兼首席会计官。在加入Wright医疗之前，Andrews女士在全球医疗器械公司美敦力公司工作了十四年。在美敦力任职期间，Andrews女士担任过多个关键财务职位，包括负责价值35亿美元的脊柱和生物制剂业务的财务副总裁（业务部门CFO）。Andrews女士的职业生涯始于田纳西州孟菲斯市的通贝和伊利诺伊州芝加哥市的Thomas Havey，LLP.Andrews女士目前是Priveterra（纳斯达克：PMGM）的董事会成员，该公司是一家专注于医疗保健的特殊收购公司，并担任其审计委员会主席。Andrews女士获得了西北印第安纳大学会计学学士学位。
- Julie B. Andrews from August 2019 to December 2020 Ms. Andrews held the position of Senior Vice President, Global Finance with Wright Medical Group N.V. Nasdaq: WMGI with responsibility for the finance, accounting, tax and treasury functions. During her time at Wright Medical, Ms. Andrews played key leadership roles in several successful mergers and acquisitions. These included leading the divestiture and carve-out of the approximately $300 million sale of the hip and knee business to Microport, providing leadership oversight for Wright Medical's $3.3 billion in equity value acquisition of Tornier, N.V., and leading the diligence and integration planning of the sale of Wright Medical to Stryker Corp. Ms. Andrews was Vice President, Chief Accounting Officer from May 2012 to September 2019 of Wright Medical Group N.V. (f.k.a. Wright Medical Group Inc.). Prior to joining Wright Medical, Ms. Andrews spent fourteen years at Medtronic, Inc., a global medical device company. During her tenure with Medtronic, Ms. Andrews held numerous key financial positions including Vice President, Finance (Business Unit CFO) for the $3.5 billion Spine and Biologics business. Ms. Andrews began her career working with Thomas & Betts Corporation in Memphis, Tennessee and Thomas Havey, LLP in Chicago, Illinois. Ms. Andrews is currently on the board of directors of Priveterra (Nasdaq: PMGM), a healthcare focused special acquisition corporation and serves as the chair of their audit committee. Ms. Andrews received a BS in Accounting from Indiana University NW.
- Raymond W. Cohen
-
Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
Raymond W. Cohen has been a member of Kestra Medical Technologies, Ltd.'s Board since 2025 and is a member of Kestra Medical Technologies, Ltd.'s audit committee and the chair of Kestra Medical Technologies, Ltd.'s compensation committee. Additionally, Mr. Cohen was a member of the board of directors of Kestra Medical Technologies, Ltd.'s subsidiary, Kestra Medical Technologies, Inc., from 2024 to 2025. Mr. Cohen is an accredited public company director and currently serves on the board, including the audit and compensation committees, of RxSight (Nasdaq: RXST), a medical technology company that makes and markets adjustable intraocular lens to customize vision after cataract surgery. He is the chairman of the board of directors of a number of privately held companies, including Biobeat Technologies, Spiro Medical, Archimedes Vascular, Resonant Link Medical and ExNuero. In addition, Mr. Cohen is also an Operating Partner of the venture fund Star51 Capital as well as a Venture Partner with Andera Partners (Paris) and Sherpa Capital Partners (Beijing). - Raymond W. Cohen，他是子公司Kestra Medical Technologies， Inc.的董事会成员，自2024年以来一直担任该职务。Cohen先生自2025年起担任董事会成员。在加入公司之前，从2013年到2024年，Cohen先生担任Axonics， Inc.（纳斯达克股票代码：AXNX）的首席执行官和董事会成员，Axonics是一家医疗设备公司，拥有可植入技术，用于治疗膀胱和肠道疾病。Cohen先生目前担任Andera Partners的风险投资顾问，并担任SoniVie Ltd.的董事会主席。此前，他曾担任BioLife Solutions Inc.（纳斯达克代码：BLFS）和BiVACOR， Inc.的董事长，并担任Spectrum Pharmaceuticals Inc.（纳斯达克代码：SPPI）和Axonics， Inc.（纳斯达克代码：AXNX）的董事会成员。Cohen获得Binghamton大学的商业管理学士学位。
- Raymond W. Cohen has been a member of Kestra Medical Technologies, Ltd.'s Board since 2025 and is a member of Kestra Medical Technologies, Ltd.'s audit committee and the chair of Kestra Medical Technologies, Ltd.'s compensation committee. Additionally, Mr. Cohen was a member of the board of directors of Kestra Medical Technologies, Ltd.'s subsidiary, Kestra Medical Technologies, Inc., from 2024 to 2025. Mr. Cohen is an accredited public company director and currently serves on the board, including the audit and compensation committees, of RxSight (Nasdaq: RXST), a medical technology company that makes and markets adjustable intraocular lens to customize vision after cataract surgery. He is the chairman of the board of directors of a number of privately held companies, including Biobeat Technologies, Spiro Medical, Archimedes Vascular, Resonant Link Medical and ExNuero. In addition, Mr. Cohen is also an Operating Partner of the venture fund Star51 Capital as well as a Venture Partner with Andera Partners (Paris) and Sherpa Capital Partners (Beijing).
高管简历
中英对照 | 中文 | 英文- Ron Kurtz
Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.- Ron Kurtz于2015年6月加入RXSight，Inc.，自2016年1月起担任总裁兼首席执行官，自2016年2月起担任董事会成员。在2015年6月加入RXSight之前，Kurtz博士联合创立了LensX Lasers，Inc.。他曾担任LensX’；的总裁兼首席执行官，直到2010年8月被AlconInc.收购，继续担任Alcon LensX，Inc.的总经理直到2015年3月。1997年，他联合创立了Intralase Corp.，并担任其总裁兼首席执行官（直到1998年11月），随后担任其副总裁兼医疗总监（直到2005年12月），之后担任咨询（直到2006年12月）。Intralase于2004年10月成为纳斯达克上市公司，并于2007年4月被Advanced Medical Optics，Inc.收购。Kurtz博士在Odos GmbH和Allegro Ekymics，Inc.的董事会任职。Kurtz博士曾在加利福尼亚大学欧文分校和密歇根大学任教。他在哈佛大学获得了生物化学学士学位，在加州大学圣地亚哥分校获得了博士学位。
- Ron Kurtz joined RxSight, Inc. in June 2015 and has served as President and Chief Executive Officer since January 2016 and as a member of board of directors since February 2016. Prior to joining RxSight in June 2015 Dr. Kurtz co-founded LenSx Lasers, Inc. He served as LenSx's President and Chief Executive Officer until its acquisition by Alcon Inc. in August 2010 continuing as General Manager of Alcon LenSx, Inc. until March 2015. In 1997 he co-founded IntraLase Corp. and served as its President & CEO until November 1998 and then as its Vice-President and Medical Director until December 2005 thereafter consulting until December 2006. IntraLase became a publicly held Nasdaq-listed company in October 2004 and was acquired by Advanced Medical Optics, Inc. in April 2007. Dr. Kurtz serves on the boards of ODOS GmbH and Allegro Ophthalmics, Inc. Dr. Kurtz has served on the faculty of both the University of California, Irvine, and the University of Michigan. He earned his B.A. in Biochemistry from Harvard College and his M.D. from the University of California, San Diego.
- Eric Weinberg
Eric Weinberg自2015年6月起担任我们的首席商务官。在加入RXSight之前，他是LensX Lasers，Inc.的联合创始人，从2008年7月到2010年8月担任首席商务官，在其被AlconInc.收购之前。2010年8月至2014年4月，他担任Alcon Lensx，Inc.外科开发副总裁。他于1999年9月加入Intralase Corp.，担任销售副总裁，后来担任全球营销高级副总裁，直到2007年4月公司被Advanced Medical Optics，Inc.收购。1993年3月至1997年10月被Bausch&Lomb，Inc.收购，Weinberg先生担任Chiron Vision Corp.屈光外科全球总监。他继续担任Bausch&Lomb的全球屈光外科主任直到1999年8月。1980年，温伯格在施坦威仪器公司（Steinway Instruments）开始了他的医疗器械职业生涯。
Eric Weinberg has served as Chief Commercial Officer since June 2015. Prior to joining RxSight, he was a co-founder of LenSx Lasers, Inc. and served as Chief Commercial Officer from July 2008 to August 2010 prior to its acquisition by Alcon Inc. He went on to serve as Vice President of Surgical Development at Alcon LenSx, Inc. from August 2010 to April 2014. He joined IntraLase Corp. in September 1999 as Vice President of Sales and later as the Senior Vice President, Global Marketing until the company was acquired by Advanced Medical Optics, Inc. in April 2007. Mr. Weinberg served as Global Director of Refractive Surgery at Chiron Vision Corp. from March 1993 until October 1997 when it was acquired by Bausch & Lomb, Inc. He continued as Global Director of Refractive Surgery at Bausch & Lomb until August 1999. Mr. Weinberg began his career in medical devices at Steinway Instruments in 1980.- Eric Weinberg自2015年6月起担任我们的首席商务官。在加入RXSight之前，他是LensX Lasers，Inc.的联合创始人，从2008年7月到2010年8月担任首席商务官，在其被AlconInc.收购之前。2010年8月至2014年4月，他担任Alcon Lensx，Inc.外科开发副总裁。他于1999年9月加入Intralase Corp.，担任销售副总裁，后来担任全球营销高级副总裁，直到2007年4月公司被Advanced Medical Optics，Inc.收购。1993年3月至1997年10月被Bausch&Lomb，Inc.收购，Weinberg先生担任Chiron Vision Corp.屈光外科全球总监。他继续担任Bausch&Lomb的全球屈光外科主任直到1999年8月。1980年，温伯格在施坦威仪器公司（Steinway Instruments）开始了他的医疗器械职业生涯。
- Eric Weinberg has served as Chief Commercial Officer since June 2015. Prior to joining RxSight, he was a co-founder of LenSx Lasers, Inc. and served as Chief Commercial Officer from July 2008 to August 2010 prior to its acquisition by Alcon Inc. He went on to serve as Vice President of Surgical Development at Alcon LenSx, Inc. from August 2010 to April 2014. He joined IntraLase Corp. in September 1999 as Vice President of Sales and later as the Senior Vice President, Global Marketing until the company was acquired by Advanced Medical Optics, Inc. in April 2007. Mr. Weinberg served as Global Director of Refractive Surgery at Chiron Vision Corp. from March 1993 until October 1997 when it was acquired by Bausch & Lomb, Inc. He continued as Global Director of Refractive Surgery at Bausch & Lomb until August 1999. Mr. Weinberg began his career in medical devices at Steinway Instruments in 1980.
- Ilya Goldshleger
Ilya Goldshleger加入RXSight，Inc.，担任工程副总裁，自2019年6月起担任我们的首席运营官。Goldshleger博士于2015年9月加入RXSight，担任工程副总裁，负责LAL和LDD系统及其附件的开发和工程。在加入RXSight之前，Goldshleger博士从2010年到2015年在Alcon LensX，Inc.担任多个管理职位，最后担任研发光学和诊断总监，从2008年10月到2010年8月被Alcon，Inc.收购，在LensX Lasers，Inc.担任多个研究与开发职位。Goldshleger博士在莫斯科物理和技术学院获得物理和数学科学硕士学位，在俄罗斯科学院获得化学物理博士学位。
Ilya Goldshleger joined RxSight, Inc. as the Vice President, Engineering and has served as Chief Operating Officer since June 2019. Dr. Goldshleger joined RxSight in September 2015 as the Vice President of Engineering and was responsible for the development and engineering of the LAL and LDD system and its accessories. Prior to joining RxSight, Dr. Goldshleger held various management roles at Alcon LenSx, Inc. from 2010 to 2015 last serving as Director, R&D Optics and Diagnostics, and held various roles in research and development at LenSx Lasers, Inc. from October 2008 to its acquisition by Alcon, Inc. in August 2010. Dr. Goldshleger received a Master of Science in Physics and Mathematics from the Moscow Institute of Physics and Technology and a Ph.D. in Chemical Physics from the Russian Academy of Sciences.- Ilya Goldshleger加入RXSight，Inc.，担任工程副总裁，自2019年6月起担任我们的首席运营官。Goldshleger博士于2015年9月加入RXSight，担任工程副总裁，负责LAL和LDD系统及其附件的开发和工程。在加入RXSight之前，Goldshleger博士从2010年到2015年在Alcon LensX，Inc.担任多个管理职位，最后担任研发光学和诊断总监，从2008年10月到2010年8月被Alcon，Inc.收购，在LensX Lasers，Inc.担任多个研究与开发职位。Goldshleger博士在莫斯科物理和技术学院获得物理和数学科学硕士学位，在俄罗斯科学院获得化学物理博士学位。
- Ilya Goldshleger joined RxSight, Inc. as the Vice President, Engineering and has served as Chief Operating Officer since June 2019. Dr. Goldshleger joined RxSight in September 2015 as the Vice President of Engineering and was responsible for the development and engineering of the LAL and LDD system and its accessories. Prior to joining RxSight, Dr. Goldshleger held various management roles at Alcon LenSx, Inc. from 2010 to 2015 last serving as Director, R&D Optics and Diagnostics, and held various roles in research and development at LenSx Lasers, Inc. from October 2008 to its acquisition by Alcon, Inc. in August 2010. Dr. Goldshleger received a Master of Science in Physics and Mathematics from the Moscow Institute of Physics and Technology and a Ph.D. in Chemical Physics from the Russian Academy of Sciences.
- Scott Gaines
- 暂无中文简介
暂无英文简介 - 暂无中文简介
- 暂无英文简介
- Mark Wilterding
Mark Wilterding，于2025年3月至2026年1月期间，担任全球领先的结构性心脏创新公司爱德华兹生命科学的全球财务高级副总裁。在这个职位上，Wilterding先生负责财务规划和分析（FP & A）、财务、区域财务、投资者关系和财务运营与战略。在最近一次任职于爱德华兹生命科学之前，Wilterding先生于2019年6月开始在爱德华兹生命科学担任过各种职务，包括高级副总裁、投资者关系、FP & A和财务主管。2014年4月至2019年6月，Wilterding先生担任董事，为全球医疗保健技术公司美敦力，投资者关系。Wilterding先生拥有圣奥拉夫学院经济学和英语学士学位以及西北大学家乐氏管理学院金融、管理和战略以及市场营销硕士学位。
Mark Wilterding,served as the senior vice president, global finance for Edwards Lifesciences, a leading global structural heart innovation company, from March 2025 to January 2026. In this role Mr. Wilterding maintained responsibility for Financial Planning and Analysis (FP&A), treasury, regional finance, investor relations and financial operations & strategy. Prior to his most recent position with Edwards Lifesciences, Mr. Wilterding served in various roles at Edwards Lifesciences beginning in June 2019, including senior vice president, investor relations, FP&A, and treasurer. From April 2014 to June 2019, Mr. Wilterding served as director, investor relations of Medtronic, a global healthcare technology company. Mr. Wilterding holds a bachelor's degree in economics and English from St. Olaf College and an M.B.A. in finance, management and strategy, and marketing from the Kellogg School of Management at Northwestern University.- Mark Wilterding，于2025年3月至2026年1月期间，担任全球领先的结构性心脏创新公司爱德华兹生命科学的全球财务高级副总裁。在这个职位上，Wilterding先生负责财务规划和分析（FP & A）、财务、区域财务、投资者关系和财务运营与战略。在最近一次任职于爱德华兹生命科学之前，Wilterding先生于2019年6月开始在爱德华兹生命科学担任过各种职务，包括高级副总裁、投资者关系、FP & A和财务主管。2014年4月至2019年6月，Wilterding先生担任董事，为全球医疗保健技术公司美敦力，投资者关系。Wilterding先生拥有圣奥拉夫学院经济学和英语学士学位以及西北大学家乐氏管理学院金融、管理和战略以及市场营销硕士学位。
- Mark Wilterding,served as the senior vice president, global finance for Edwards Lifesciences, a leading global structural heart innovation company, from March 2025 to January 2026. In this role Mr. Wilterding maintained responsibility for Financial Planning and Analysis (FP&A), treasury, regional finance, investor relations and financial operations & strategy. Prior to his most recent position with Edwards Lifesciences, Mr. Wilterding served in various roles at Edwards Lifesciences beginning in June 2019, including senior vice president, investor relations, FP&A, and treasurer. From April 2014 to June 2019, Mr. Wilterding served as director, investor relations of Medtronic, a global healthcare technology company. Mr. Wilterding holds a bachelor's degree in economics and English from St. Olaf College and an M.B.A. in finance, management and strategy, and marketing from the Kellogg School of Management at Northwestern University.